Stephen Barat is Senior VP of Therapeutics at HTG MOLECULAR DIAGNOSTICS, INC (HTGM). They have made 1 open-market trade across 1 company since 2023, most recently 2023-06-08.
CIK 0001965244
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| HTGM | 421 | $202 |
Shares reported on the most recent Form 4, priced at the 2023-06-09 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| HTGM | SELL | 2023-06-08 | 2023-06-09 | $0.80 | $710 | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.